Variant position: 403 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 2009 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human FWENLYQLTLRAAGKTYMIF FVLVIFLGSFYLINLILAVVA
Mouse FWENLYQLTLRAAGKTYMIF FVLVIFLGSFYLINLILAVVA
Rat FWENLYQLTLRAAGKTYMIF FVLVIFLGSFYLINLILAVVA
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 2009 Sodium channel protein type 1 subunit alpha
400 – 420 Helical; Name=S6 of repeat I
110 – 454 I
De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study.
Berkovic S.F.; Harkin L.; McMahon J.M.; Pelekanos J.T.; Zuberi S.M.; Wirrell E.C.; Gill D.S.; Iona X.; Mulley J.C.; Scheffer I.E.;
Lancet Neurol. 5:488-492(2006)
Cited for: VARIANTS EIEE6 LEU-403; ASN-413; HIS-946; ASP-1238; GLY-1396 AND GLN-1645;
The spectrum of SCN1A-related infantile epileptic encephalopathies.
Harkin L.A.; McMahon J.M.; Iona X.; Dibbens L.; Pelekanos J.T.; Zuberi S.M.; Sadleir L.G.; Andermann E.; Gill D.; Farrell K.; Connolly M.; Stanley T.; Harbord M.; Andermann F.; Wang J.; Batish S.D.; Jones J.G.; Seltzer W.K.; Gardner A.; Sutherland G.; Berkovic S.F.; Mulley J.C.; Scheffer I.E.;
Cited for: VARIANTS CYS-393; PRO-395; GLU-422; GLY-626; VAL-1480; SER-1543; GLN-1636 AND HIS-1657; VARIANTS EIEE6 HIS-79; CYS-84; TRP-101; ARG-199; MET-226; THR-239; LEU-403; ASN-413; GLY-674; PRO-783; GLU-944; LEU-945; GLU-950; ASP-1238; MET-1390; GLY-1396; PRO-1441; VAL-1545; CYS-1596; GLN-1645; VAL-1707; ARG-1721 AND THR-1922; VARIANT GEFS+2 VAL-973;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.